Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: Presentation of interim findings from ongoing phase 1 studies

Acta Neurochirurgica, Supplementum

Volumn , Issue 88, 2003, Pages 105-111

  Kunvvar, S ^a  

^a Box 0112 ^*  (United States)

Author keywords

Convection enhanced delivery; IL 13; Immunotoxins

Indexed keywords

EID: 77952461038     PISSN: 00651419     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6090-9_16     Document Type: Review

References (30)

1. Bobo R, Laske D, Akbasak A et al (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci 91: 2076-2080
2. Bochner B, Klunk D, Sterbinski S et al (1995) IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 154: 799-803
3. Brem H, Piantadosi S, Burger P et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345: 1008-1012
4. Chen M, Lonser R, Morrison P et al (1999) Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90: 315-320
5. Debinski W, Obiri N, Pastan I et a! (1995a) A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 270: 16775-16780
6. Debinski W, Obiri N, Powers S et al (1995b) Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res I: 1253-1258
7. Debinski W, Miner R, Leiand P et al (1996) Receptor for interleukin 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J Biol Chem 271:22428-22433
8. Debinski W, Gibo D, Hulet S et al (1999a) Receptor for interleukin 13 is a marker and therapeutic target for human high grade gliomas. Clin Cancer Res 5:985-990
9. Debinski W, Gibo D, Slagle B et al (1999b) Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int J Oncol 15:481-486
10. Defrance T, Carayon P, Billian G et al ( 1994) Interleukin 13 is a B cell stimulating factor. J Exp Med 179: 135-143
11. Derocq J, Segui M, Poinot-Chazel C et al (1994) Interleukin-13 stimulates interIeukin-6 production by human keratinocytes. Similarity with interleukin-4. FEBS Lett 343: 32-36
12. Goebeler M, Schnarr B, Toksoy A et al (1997) Interleukin-13 selectively induces monocyte chemoattractant protein-1 synthesis and secretion by human endothelial cells. Involvement of IL-4R alpha and Stat6 phosphorylation. Immunology 91:450-457
13. Husain S, Joshi B, Puri RK (2001) Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92: 168-175
14. Kawakami M, Kawakami K, Puri R (2002) Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther 1: 999-1007
15. Kreitman R, Pastan I (1998) Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 58: 968-975
16. Kunwar S, Pai L, Pastan I (1993) Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J Neurosurg 79: 569-576
17. Kunwar S, Prados M, Lang F (2003) Intratumoral and peritu-moral convection enhanced delivery (CED) of IL13-PE38QQR, a recombinant tumor-targeted cytotoxin, in recurrent malignant glioma-phase I trial. J Neurosurg 98 (Abstract accepted for presentation at American Association Neurological Surgeons Meeting)
18. Laske D, Youle R, Oldfield E (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 12: 1362-1368
19. Lieberman D, Laske D, Morrison P et al (1995) Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82: 1021-1029
20. Morrison P, Laske D, Bob H et al (1994) High-flow micro-infusion: tissue penetration and pharmacodynamics. Am J Physiol 266: R292-R305
21. Murata T, Obiri N, Debinski W et al (1997) Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 238:90-94
22. Murata T, Taguchi J, Puri R (1998) Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. Blood 91: 3884-3891
23. Pastan I, FitzGerald D (1991) Recombinant toxins for cancer treatment. Science 254: 1173
24. Prabhu S, Broaddus W, Gillies G et al (1998) Distribution of macromolecular dyes in brain using positive pressure infusion: a model for direct controlled delivery of therapeutic agents. Surg Neurol 50: 367-375
25. Puri R, Hoon D, Leiand P et al (1996) Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 24: 5631-5637
26. Schnyder B, Lugli S, Feng N et al (1996) Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain. Blood 87: 4286-4295
27. Sironi M, Sciacca F, Matteucci C et al (1994) Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interIeukin-6 production. Blood 84: 1913-1921
28. Weingart J, Strauss L, Grossman S et al (2002) Phase I/II study: intra-tumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma. Newoond 4(4): 379
29. Yung W, Prados M, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17(9): 2762-2771
30. Yung W, Albright R, Olson J et al (2000) A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5): 588-593